表紙
市場調査レポート

遺伝子疾患関連の提携条件・契約

Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 263658
出版日 ページ情報 英文 500+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
遺伝子疾患関連の提携条件・契約 Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials
出版日: 2016年02月01日 ページ情報: 英文 500+ Pages
概要

当レポートでは、世界の遺伝子疾患市場における企業提携契約の締結動向とその内容(提携条件)について分析し、近年の提携契約/取引の形成状況と特徴(種類別・開発段階別・適応症別)、平均的な取引条件、代表的な契約の概略、大手医薬品企業の動向、近年の提携取引一覧とその内訳といった情報を盛り込んで、概略以下の内容でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 遺伝子疾患関連の取引形成の動向

  • イントロダクション
  • 近年の遺伝子疾患関連の提携動向
  • 大手医薬品企業の遺伝子疾患関連の契約締結活動
  • 遺伝子疾患分野で活発に活動していない大手製薬企業
  • 遺伝子疾患関連の提携:取引の種類別
  • 遺伝子疾患関連の提携:産業別
  • 遺伝子疾患関連の提携:開発段階別
  • 遺伝子疾患関連の提携:技術の種類別
  • 遺伝子疾患関連の提携:適応症別
  • 遺伝子疾患関連の提携の平均的な契約条件
    • 取引総額
    • 前払い金
    • マイルストーン払い
    • ロイヤルティ率

第3章 代表的な遺伝子疾患関連の契約

  • イントロダクション
  • 代表的な契約:金額別
  • 大手製薬企業が参加している代表的な契約

第4章 大手医薬品企業の遺伝子疾患関連の提携契約

  • イントロダクション
  • 大手医薬品企業との提携契約の活用方法
  • 大手医薬品企業のプロファイル(全31社)

第5章 遺伝子疾患関連の提携契約の一覧

  • イントロダクション
  • 取引の種類別
  • 開発段階別
  • 技術の種類別

第6章 治療標的別の契約締結動向

  • イントロダクション
  • 治療標的別の契約動向
    • 遺伝子疾患
    • ハンチントン病
    • ダウン症候群
    • 嚢胞性繊維症
    • かま状赤血球
    • 神経線維腫症
    • 脆弱X症候群
    • 遺伝性血管浮腫
    • その他

第7章 提携リソースセンター

  • オンライン提携
  • 提携動向
  • 関連調査

付録

  • 付録1 遺伝子疾患関連の契約の一覧:企業別(ABC順)
  • 付録2 遺伝子疾患関連の契約の一覧:契約の種類別
  • 付録3 遺伝子疾患関連の契約の一覧:開発段階別
  • 付録4 遺伝子疾患関連の契約の一覧:技術の種類別
  • 付録5 契約の種類の定義

Wildwood Venturesについて

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2218

Global Genetic disorders Partnering 2010-2016: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the genetic disorders partnering deals and agreements entered into by the worlds leading healthcare companies

Global Genetic Disorders Partnering 2010 to 2016 provides the full collection of Genetic Disorders disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Genetic Disorders partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Genetic Disorders partnering agreement structure
  • Genetic Disorders partnering contract documents
  • Top Genetic Disorders deals by value
  • Most active Genetic Disorders dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Genetic Disorders disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genetic Disorders deals.

The report presents financial deal terms values for Genetic Disorders deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Genetic Disorders dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Genetic Disorders dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Genetic Disorders deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Genetic Disorders dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Genetic Disorders deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Genetic Disorders partnering deals by specific Genetic Disorders target announced since 2010. The chapter is organized by specific Genetic Disorders therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Genetic Disorders partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Genetic Disorders partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Genetic Disorders technologies and products.

Report scope

Global Genetic Disorders Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Genetic Disorders trends and structure of deals entered into by leading companies worldwide.

Global Genetic Disorders Partnering 2010 to 2016 includes:

  • Trends in Genetic Disorders dealmaking in the biopharma industry since 2010
  • Analysis of Genetic Disorders deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Genetic Disorders deal contract documents
  • Comprehensive access to over 3500 Genetic Disorders deal records
  • The leading Genetic Disorders deals by value since 2010
  • Most active Genetic Disorders dealmakers since 2010

In Global Genetic Disorders Partnering 2010 to 2016, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Genetic Disorders Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 400 genetic disorders deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Genetic Disorders Partnering 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of Genetic Disorders deal trends since 2010
  • Access Genetic Disorders deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Genetic Disorders partner companies
  • Comprehensive access to over 750 links to actual Genetic Disorders deals entered into by the world's biopharma companies
  • Indepth review of Genetic Disorders deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Genetic Disorders opportunities
  • Uncover companies actively partnering Genetic Disorders opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Genetic Disorders dealmaking

  • 2.1. Introduction
  • 2.2. Genetic Disorders partnering over the years
  • 2.3. Genetic Disorders partnering by deal type
  • 2.4. Genetic Disorders partnering by industry sector
  • 2.5. Genetic Disorders partnering by stage of development
  • 2.6. Genetic Disorders partnering by technology type
  • 2.7. Genetic Disorders partnering by therapeutic indication

Chapter 3 -Financial deal terms for Genetic Disorders partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Genetic Disorders partnering
  • 3.3. Genetic Disorders partnering headline values
  • 3.4. Genetic Disorders deal upfront payments
  • 3.5. Genetic Disorders deal milestone payments
  • 3.6. Genetic Disorders royalty rates

Chapter 4 - Leading Genetic Disorders deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Genetic Disorders partnering
  • 4.3. List of most active dealmakers in Genetic Disorders
  • 4.4. Top Genetic Disorders deals by value

Chapter 5 - Genetic Disorders contract document directory

  • 5.1. Introduction
  • 5.2. Genetic Disorders partnering deals where contract document available

Chapter 6 - Genetic Disorders dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Genetic Disorders therapeutic target

Appendices

  • Appendix 1 - Directory of Genetic Disorders deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Genetic Disorders deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Genetic Disorders deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Genetic Disorders deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Genetic Disorders partnering since 2010
  • Figure 2: Genetic Disorders partnering by deal type since 2010
  • Figure 3: Genetic Disorders partnering by industry sector since 2010
  • Figure 4: Genetic Disorders partnering by stage of development since 2010
  • Figure 5: Genetic Disorders partnering by technology type since 2010
  • Figure 6: Genetic Disorders partnering by indication since 2010
  • Figure 7: Genetic Disorders deals with a headline value
  • Figure 8: Genetic Disorders deals with upfront payment values
  • Figure 9: Genetic Disorders deals with milestone payment
  • Figure 10: Genetic Disorders deals with royalty rates
  • Figure 11: Active Genetic Disorders dealmaking activity- 2010 to 2016
  • Figure 12: Top Genetic Disorders deals by value since 2010
Back to Top